Can Amyris Walk Its Risky Tightrope and Reward Investors?

The financial situation at Amyris is not optimal for investors. Can the company squeak through the year with the aid of Total and Boeing on its way to rewarding long-term investors?

May 15, 2014 at 11:38AM

Synthetic biology pioneer Amyris (NASDAQ:AMRS) and its investors discovered several errors in the initial approach to start and ramp the company's wholly owned facility in Brotas, Brazil. While those problems would have been exposed with or without a pristine balance sheet (Amyris wasn't scaling biology with an engineering mind-set) and the company appears to be on the right track now, Amyris continues to carry the financial baggage from past operational inefficiencies. Sure, well-established partners and potential customers such as Total (NYSE:TOT) and Boeing (NYSE:BA) have emerged to support the company's development and potential revenue growth, but the balance sheet remains the biggest risk to investors.

Amyris disclosed worrisome information in its latest 10-K: The inability to secure additional financing and collaboration revenue in 2014 could adversely affect the company's business plans and its status as a going concern. It's clear that the company is walking a risky tightrope and it plays out quite simply. Should management string along enough financing and collaboration deals and plug away with operations at Brotas, Amyris will meet 2014 guidance for cash flow positive operations and the stage will be set for years of incredible growth. Should management fail to secure adequate financing or any significant portion of its collaboration inflows, Amyris will face more dire circumstances -- perhaps with long-term consequences.

Do the potential benefits outweigh the risks? Or should investors avoid a risky and unstable Amyris?

Real progress
The company successfully restarted operations in the first quarter at Brotas after planned downtime resulting from the sugarcane interharvest period in Brazil, which was used to upgrade process equipment. The enhancements have allowed Amyris to achieve production runs better than those achieved in 2013, which saw farnesene production costs of just $3.50 per liter at the time. That's still way too costly to produce bulk volumes of fuel for Total, and even too expensive to produce niche fuels for Boeing, but management understands it won't achieve profitability with fuel products. The major discrepancy in product revenue and cost of revenue will continue to reflect that reality until more profitable products increase their presence in the company's portfolio.

That reality may be closer than most investors think. An average selling price of $9.84 per liter of product was achieved in the first quarter, although that includes the new fragrance molecule patchouli oil (completely separate from farnesene) that has unknown production costs. Nonetheless, the company expects to achieve similar selling prices -- equivalent to $9,000 per metric ton -- across its platform for the next several years, which would enable gross cash margins greater than 60%.


Can Amyris hit its lofty expectations for product revenue next year and beyond? Source: Amyris.

Several other goals look very achievable for 2014. Product sales are still guided to hit the target range of $40 million to $45 million (squalane will generate $15 million to $18 million, patchouli will generate $9 million to $10 million, and the balance will be various fuel products), operating expenses continue to plunge (a 14% reduction was witnessed in the first quarter compared to the year-ago period), and cash increased to $49 million. Investors will also be comforted to know that Amyris has recorded at least $59 million in collaboration inflows in each of the past three years, which seems to make its goal for the year quite attainable. Unfortunately, continued product development is contingent on meeting specific collaboration revenue goals.

Real danger
CEO John Melo told investors that, as of March 31, the company had successfully contracted over 50% of its targeted $60 million to $70 million in collaboration inflows for the year. That sounds great at first blush, and a strain engineering collaboration with the world's largest chemical company announced at the beginning of the second quarter will certainly help, but investors remain unaware how much was already due to Amyris. It appears that the market is giving more weight to the "what ifs?"

Should Amyris fail to receive $60 million in collaboration revenue, fail to achieve $40 million in product sales, fail to find enough cash to fund operations or payback its debts, and/or fail to lower operating expenses to $85 million for the year (a 25% reduction compared with last year) then it probably won't achieve cash flow-positive operations. In a worst-case scenario, Amyris would have to slash personnel and curtail research and strain development operations, which could have a significant effect on its ability to reach its long-term goals by the end of the decade.


Strain development has come a long way to enable 2-4 new commercial strains each year. Source: Amyris.

Amyris sneaked the following financial nugget into its quarterly press release but did not mention it on the call or in its presentation: "Based on favorable market conditions, [Amyris is] exploring potential opportunistic financing of up to $100 million in the form of convertible debt." I would say the market conditions aren't so favorable right now, but securing an additional $100 million in cash before the end of the year would certainly be advantageous, albeit dilutive, for investors. The extra cash would allow the company to pursue several high-priority growth opportunities and put the company in an unfamiliar position: relatively stable financial footing, if only for a few quarters. Let's face it: A debt offering with established backers would be better than bankruptcy.

What should investors do?
Investors need to acknowledge the risk of an investment in Amyris. The financial circumstances are less than favorable and could have long-lasting and painful consequences in a worst-case scenario. I believe the potential opportunities for the company's synthetic biology platform are well within reach -- it just has to walk the tightrope in 2014 to open up multiple high-growth opportunities. That's why I'm invested in the company (I'm also young enough to take on a little more risk than most). If you believe the financial risks are greater than the long-term rewards in the cosmetic, high performance material, fragrance, and fuel markets, then you shouldn't invest. But if you feel comfortable taking on a high-risk investment for the potential to capture incredible long-term gains, then you may be able to expose a small piece of your portfolio to Amyris' platform.

Amyris too risky? Try the American energy bonanza! 
Pioneering a new field could be very rewarding for Amyris investors, but it has proved extremely costly, too. Meanwhile, record oil and natural gas production is revolutionizing the United States' energy position. Finding the right plays while historic amounts of capital expenditures are flooding the industry will pad your investment nest egg. For this reason, The Motley Fool is offering a look at three energy companies using a small IRS "loophole" to help line investor pockets. Learn this strategy, and the energy companies taking advantage, in our special report "The IRS Is Daring You to Make This Energy Investment." Don't miss out on this timely opportunity; click here to access your report -- it's absolutely free. 

Maxx Chatsko owns shares of Amyris. Check out his personal portfolioCAPS page, or previous writing for The Motley Fool, or his work for SynBioBeta to keep up with developments in the synthetic biology industry.

The Motley Fool recommends Total. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

4 in 5 Americans Are Ignoring Buffett's Warning

Don't be one of them.

Jun 12, 2015 at 5:01PM

Admitting fear is difficult.

So you can imagine how shocked I was to find out Warren Buffett recently told a select number of investors about the cutting-edge technology that's keeping him awake at night.

This past May, The Motley Fool sent 8 of its best stock analysts to Omaha, Nebraska to attend the Berkshire Hathaway annual shareholder meeting. CEO Warren Buffett and Vice Chairman Charlie Munger fielded questions for nearly 6 hours.
The catch was: Attendees weren't allowed to record any of it. No audio. No video. 

Our team of analysts wrote down every single word Buffett and Munger uttered. Over 16,000 words. But only two words stood out to me as I read the detailed transcript of the event: "Real threat."

That's how Buffett responded when asked about this emerging market that is already expected to be worth more than $2 trillion in the U.S. alone. Google has already put some of its best engineers behind the technology powering this trend. 

The amazing thing is, while Buffett may be nervous, the rest of us can invest in this new industry BEFORE the old money realizes what hit them.

KPMG advises we're "on the cusp of revolutionary change" coming much "sooner than you think."

Even one legendary MIT professor had to recant his position that the technology was "beyond the capability of computer science." (He recently confessed to The Wall Street Journal that he's now a believer and amazed "how quickly this technology caught on.")

Yet according to one J.D. Power and Associates survey, only 1 in 5 Americans are even interested in this technology, much less ready to invest in it. Needless to say, you haven't missed your window of opportunity. 

Think about how many amazing technologies you've watched soar to new heights while you kick yourself thinking, "I knew about that technology before everyone was talking about it, but I just sat on my hands." 

Don't let that happen again. This time, it should be your family telling you, "I can't believe you knew about and invested in that technology so early on."

That's why I hope you take just a few minutes to access the exclusive research our team of analysts has put together on this industry and the one stock positioned to capitalize on this major shift.

Click here to learn about this incredible technology before Buffett stops being scared and starts buying!

David Hanson owns shares of Berkshire Hathaway and American Express. The Motley Fool recommends and owns shares of Berkshire Hathaway, Google, and Coca-Cola.We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

©1995-2014 The Motley Fool. All rights reserved. | Privacy/Legal Information

Compare Brokers